293 related articles for article (PubMed ID: 26228486)
41. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.
Szeimies RM; Bichel J; Ortonne JP; Stockfleth E; Lee J; Meng TC
Br J Dermatol; 2008 Jul; 159(1):205-10. PubMed ID: 18476957
[TBL] [Abstract][Full Text] [Related]
42. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
43. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.
Huen AO; Rook AH
Curr Opin Oncol; 2014 Mar; 26(2):237-44. PubMed ID: 24441505
[TBL] [Abstract][Full Text] [Related]
44. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
[TBL] [Abstract][Full Text] [Related]
45. Topical treatment of early cutaneous T-cell lymphoma.
Ramsay DL; Meller JA; Zackheim HS
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1031-56. PubMed ID: 8522483
[TBL] [Abstract][Full Text] [Related]
46. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
47. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
Foss FM
Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
[TBL] [Abstract][Full Text] [Related]
48. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL.
Kirsch IR; Watanabe R; O'Malley JT; Williamson DW; Scott LL; Elco CP; Teague JE; Gehad A; Lowry EL; LeBoeuf NR; Krueger JG; Robins HS; Kupper TS; Clark RA
Sci Transl Med; 2015 Oct; 7(308):308ra158. PubMed ID: 26446955
[TBL] [Abstract][Full Text] [Related]
49. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.
Rook AH; Kuzel TM; Olsen EA
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1435-48, ix. PubMed ID: 14710894
[TBL] [Abstract][Full Text] [Related]
50. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
51. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
52. New Genetic Markers of Skin T-Cell Lymphoma Treatment.
Vašků V; Fialová P; Vašků A
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540417
[TBL] [Abstract][Full Text] [Related]
53. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy.
Heald P; Rook A; Perez M; Wintroub B; Knobler R; Jegasothy B; Gasparro F; Berger C; Edelson R
J Am Acad Dermatol; 1992 Sep; 27(3):427-33. PubMed ID: 1401279
[TBL] [Abstract][Full Text] [Related]
54. Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma.
Greiner D; Olsen EA; Petroni G
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):950-5. PubMed ID: 9204061
[TBL] [Abstract][Full Text] [Related]
55. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma.
Zane C; Venturini M; Sala R; Calzavara-Pinton P
Photodermatol Photoimmunol Photomed; 2006 Oct; 22(5):254-8. PubMed ID: 16948827
[TBL] [Abstract][Full Text] [Related]
56. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
57. Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma.
Theurich S; Schlaak M; Steguweit H; Heukamp LC; Wennhold K; Kurschat P; Rabenhorst A; Hartmann K; Schlösser H; Shimabukuro-Vornhagen A; Holtick U; Hallek M; Stadler R; von Bergwelt-Baildon M
J Clin Oncol; 2016 Apr; 34(12):e110-6. PubMed ID: 25348001
[No Abstract] [Full Text] [Related]
58. Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.
Gaydosik AM; Tabib T; Geskin LJ; Bayan CA; Conway JF; Lafyatis R; Fuschiotti P
Clin Cancer Res; 2019 Jul; 25(14):4443-4454. PubMed ID: 31010835
[TBL] [Abstract][Full Text] [Related]
59. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
60. Follicular cutaneous T-cell lymphoma: a clinicopathological study of nine cases.
Hodak E; Feinmesser M; Segal T; Yosipovitch G; Lapidoth M; Maron L; Bergman R; Sahar D; David M
Br J Dermatol; 1999 Aug; 141(2):315-22. PubMed ID: 10468808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
